Skip to main content
. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634

Figure 1.

Figure 1

Study schedule SAKK 06/19: intravesical rBCG followed by perioperative chemoimmunotherapy for patients with muscle-invasive bladder cancer. A multicentre, single-arm phase 2 trial. rBCG, recombinant BCG.